Innovus Pharmaceuticals Reports Record Annual Revenues for the Full Year 2016 of $4.8 Million
Company Affirms Revenue Guidance of $15 Million for Fiscal Year 2017
SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB: INNV), today
announced full year 2016 net revenues of $4.8 million compared to $0.7
million in revenues for the same period in 2015 and fourth quarter of
2016 net revenues of $1.7 million compared to $0.2 million in revenues
for the same period in 2015.
“We believe our revenue growth for all of 2016 highlights the strength
of our Beyond Human® Sales and Marketing platform that we acquired in
March 2016 along with the high value products we are commercializing,”
stated Bassam Damaj, President and Chief Executive Officer of Innovus
Pharma. “Looking forward to 2017, we continue to be focused on
increasing annual revenues to $15 million by executing on our goals of
expanding our product lines and making our products commercially
available in the United States and outside of the United States through
our partners, and achieving profitability.”
Financial highlights for the year ended December 31, 2016 included:
-
Net revenues totaled $4.8 million for the year ended December 31,
2016, compared to net revenues of $0.7 million for the year ended
December 31, 2015. -
Gross margins increased to 77.5% for the year ended December 31, 2016,
compared to 53.4% for the year ended December 31, 2015. -
Total operating expenses increased to $10.7 million and included $2.7
million in non-cash share-based compensation for the year ended
December 31, 2016. -
Net loss totaled $13.7 million, or $0.15 per common share, for the
year ended December 31, 2016. The net loss included interest expense
of $6.7 million, of which $6.4 million was non-cash and related to
amortization of debt discounts and the excess initial fair value of
the embedded conversion features from our 2016 financing. The net loss
also included a non-cash expense of $1.3 million for the net change in
fair value of contingent consideration. Net loss for the year ended
December 31, 2015 totaled $4.2 million or $0.08 per common share.
Financial highlights for the three months ended December 31, 2016
included:
-
Net revenues totaled $1.7 million for the three months ended December
31, 2016, compared to net revenues of $0.2 million for the three
months ended December 31, 2015. -
Gross margins increased to 78.2% for the three months ended December
31, 2016, significantly higher than gross margins for the three months
ended December 31, 2015 which totaled 44.3%. -
Total operating expenses increased to $3.6 million and included $0.8
million in non-cash share-based compensation for the three months
ended December 31, 2016. -
Net loss totaled $3.4 million, or $0.03 per common share, for the
three months ended December 31, 2016. The net loss included a non-cash
expense of $1.5 million for the net change in fair value of contingent
consideration. The net loss also included interest expense of $0.7
million, of which $0.6 million was non-cash and related to
amortization of debt discounts and the excess initial fair value of
the embedded conversion feature from our 2016 financing. Net loss for
the three months ended December 31, 2015 totaled $1.0 million or $0.02
per common share. - Cash balance totaled $0.8 million at December 31, 2016.
Fourth quarter 2016 and recent developments:
-
Notification was received to commercialize Zestra® in all 28 member
countries of the European Union. -
Zestra® was approved for sale in South Korea through its partner J&H
Co. LTD. -
Mr. Randy Berholtz was appointed as Executive Vice President,
Corporate Development and General Counsel. -
Lertal® tablets, a clinically proven supplement for the relief of
allergic rhinitis symptoms from NTC was in-licensed for the United
States and Canada. Product will be launched under the brand name
AllerVarx™. -
UriVarx™, clinically proven to reduce urinary urgency, accidents and
both day and night frequency in Overactive Bladder (OAB) and Urinary
Incontinence (UI), was launched under the Beyond Human® Sales and
Marketing Platform. -
Entered into a $2.0 million per year exclusive license and
distribution agreement with J&H Co. LTD granting them exclusive rights
to market and sell Zestra® in South Korea. -
Zestra® multi-dose form for female sexual arousal, was launched under
the Beyond Human® Sales and Marketing Platform in the U.S. -
Entered into an exclusive license and distribution agreement with Elis
Pharmaceuticals granting Elis exclusive license to market and sell
Zestra® in Lebanon. -
Initiated a pre-clinical and clinical program intended to evaluate the
safety and efficacy of the combination of its supplement Vesele® for
promoting sexual health with sildenafil indicated for treating
erectile dysfunction.
The Company will host a conference call at 4:30 p.m. ET/1:30 p.m. PT
today to discuss the financial results and recent business developments.
To participate in the call, please dial 1-877-883-0383 for domestic
callers or 1-412-902-6506 for international callers. Participant Elite
Entry Number: 5095822. A replay of the call will be available for 30
days. To access the replay, dial 1-877-344-7529 domestically or
1-412-317-0088 internationally and reference Conference ID: 10102614.
The replay will be available shortly after the end of the conference
call.
|
Consolidated Statements of Operations |
||||||||||||||||||||||||
| Three months ended | Year ended | |||||||||||||||||||||||
| December 31, | December 31, | |||||||||||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||
| Net Revenues | ||||||||||||||||||||||||
| Product sales, net | $ | 1,691,491 | $175,648 | $ | 4,817,603 | $730,717 | ||||||||||||||||||
| License revenue | – | – | 1,000 | 5,000 | ||||||||||||||||||||
| Total net revenues | 1,691,491 | 175,648 | 4,818,603 | 735,717 | ||||||||||||||||||||
| Operating Expenses | ||||||||||||||||||||||||
| Cost of product sales | 368,810 | 97,905 | 1,083,094 | 340,713 | ||||||||||||||||||||
| Research & development | 30,137 | – | 77,804 | – | ||||||||||||||||||||
| Sales & marketing | 1,363,879 | – | 3,621,045 | 82,079 | ||||||||||||||||||||
| General & administrative | 1,858,215 | 829,001 | 5,870,572 | 3,828,113 | ||||||||||||||||||||
| Impairment of goodwill | – | 759,428 | – | 759,428 | ||||||||||||||||||||
| Total operating expenses | 3,621,041 | 1,686,334 | 10,652,515 | 5,010,333 | ||||||||||||||||||||
| Loss from operations | (1,929,550 | ) | (1,510,686 | ) | (5,833,912 | ) | (4,274,616 | ) | ||||||||||||||||
| Other Income and (Expenses) | ||||||||||||||||||||||||
| Interest expense | (660,942 | ) | (408,650 | ) | (6,661,694 | ) | (1,153,376 | ) | ||||||||||||||||
| Loss on extinguishment of debt | – | – | – | (32,500 | ) | |||||||||||||||||||
| Other income (expense), net | (190 | ) | (8,495 | ) | 1,649 | (8,495 | ) | |||||||||||||||||
| Fair value adjustment for contingent consideration | (1,464,638 | ) | 115,822 | (1,269,857 | ) | 115,822 | ||||||||||||||||||
| Change in fair value of derivative liabilities | 697,687 | 77,131 | 65,060 | 393,509 | ||||||||||||||||||||
| Total other expense, net | (1,428,083 | ) | (224,192 | ) | (7,864,842 | ) | (685,040 | ) | ||||||||||||||||
| Loss before provision for (benefit from) income taxes | (3,357,633 | ) | (1,734,878 | ) | (13,698,754 | ) | (4,959,656 | ) | ||||||||||||||||
| Provision for (benefit from) income taxes | 2,400 | (757,028 | ) | 2,400 | (757,028 | ) | ||||||||||||||||||
| Net loss | $ | (3,360,033 | ) | $(977,850 | ) | $ | (13,701,154 | ) | $(4,202,628 | ) | ||||||||||||||
| Net loss per share of common stock – basic and diluted: |
$ |
(0.03 |
) |
$ (0.02 |
) |
$ |
(0.15 |
) |
$ (0.08 |
) |
||||||||||||||
|
Weighted average number of shares of common stock outstanding – basic and diluted |
116,765,431 |
59,685,945 |
94,106,382 |
52,517,530 |
||||||||||||||||||||
|
Condensed Consolidated Balance Sheet Data |
|||||||||||
| December 31, 2016 | December 31, 2015 | ||||||||||
|
1 |
1 |
||||||||||
| Assets | |||||||||||
| Cash | $ | 829,933 | $ | 55,901 | |||||||
| Accounts receivable, net | 33,575 | 83,097 | |||||||||
| Prepaid expenses & other current assets | 863,664 | 53,278 | |||||||||
| Inventories | 599,856 | 254,443 | |||||||||
| Intangible assets & other non-current assets | 5,900,350 | 5,900,286 | |||||||||
| Total assets | $ | 8,227,378 | $ | 6,347,005 | |||||||
| Liabilities & Stockholders’ Equity (Deficit) | |||||||||||
| Accounts payable & accrued liabilities | $ | 1,210,050 | $ | 155,503 | |||||||
| Total accrued compensation | 2,299,593 | 1,442,790 | |||||||||
| Deferred revenue & customer deposits | 11,000 | 24,079 | |||||||||
| Accrued interest payable | 47,782 | 79,113 | |||||||||
| Total notes payable and non-convertible debenture, net of discount | 681,127 | 303,551 | |||||||||
| Total derivative liabilities | 483,744 | 734,572 | |||||||||
| Total contingent consideration | 1,685,917 | 3,229,804 | |||||||||
|
Total line of credit convertible debenture and non-convertible debenture – related party, net of discount |
– | 416,472 | |||||||||
| Convertible debentures, net of discount | 714,192 | 407,459 | |||||||||
| Total stockholders’ equity (deficit) | 1,093,973 | (446,338 | ) | ||||||||
| Total liabilities & stockholders’ equity (deficit) | $ | 8,227,378 | $ | 6,347,005 | |||||||
1 The Condensed Consolidated Balance Sheet Data has
been derived from the audited consolidated financial statements as of
that date.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging
over-the-counter (“OTC”) consumer goods and specialty pharmaceutical
company engaged in the commercialization, licensing and development of
safe and effective non-prescription medicine and consumer care products
to improve men’s and women’s health and vitality and respiratory
diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and
health products, which we market directly; (b) commercial partners to
primary care physicians, urologists, gynecologists and therapists; and
(c) directly to consumers through our on-line channels, retailers and
wholesalers. The Company is dedicated to being a leader in developing
and marketing new OTC and branded Abbreviated New Drug Application
(“ANDA”) products. The Company is actively pursuing opportunities where
existing prescription drugs have recently, or are expected to, change
from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com,
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com.
Innovus Pharma’s Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, its financial results, projected revenues, projected online
subscribers and other customers, estimated markets for its products, and
statements about achieving its other corporate and business development,
growth, commercialization, financial and staffing objectives. Readers
are cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company’s most recent filing on Form
S-1, annual report on Form 10-K, subsequent quarterly reports filed on
Form 10-Q and other filings made with the SEC. Copies of these reports
are available from the SEC’s website or without charge from the Company.
Contacts
Chesapeake Group
Kevin Holmes, 410-825-3930
info@chesapeakegp.com
